Saturday 17 October 2026
Export ACAD’s income statement to Excel — free account
ACADIA Pharmaceuticals Inc.
ACAD Healthcare Biotechnology
ACADIA Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.1 billion, up 11.9% from fiscal 2024. In the quarter to June 2026, revenue grew 16.4%, EPS grew 12.5% and free cash flow grew 50.3%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.
19.12
0.59
−2.99%
Follow ACAD
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
11.51 | 13.49 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
6 | 4 | 5 | 4 | 4 | 4 | 6 | 6 | 5 | 3 |
Altman Z-Score |
7.90 | 3.41 | 6.38 | 3.00 | 10.59 | 29.17 | 42.35 | 16.22 | 39.37 | 44.08 |
P/S ratio |
4.20 | 3.17 | 6.96 | 5.10 | 7.74 | 19.04 | 18.57 | 9.15 | 29.87 | 192.33 |
P/FCF ratio |
0.00 | 25.96 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
3.79 | (0.05) | (6.64) | (9.19) | (3.21) | (1.37) | 5.27 | 1.95 | (2.80) | 9.95 |
Beneish M-Score |
(0.89) | (2.27) | (2.45) | (3.42) | (2.32) | (2.69) | (2.44) | (2.50) | 1.51 | 250.24 |
P/Operating CF |
(92.28) | 75.31 | 59.21 | (110.62) | (162.02) | (305.98) | (211.98) | (52.38) | (124.79) | (54.47) |
P/B ratio |
3.66 | 4.15 | 11.71 | 6.59 | 6.93 | 13.41 | 9.01 | 4.27 | 11.13 | 6.43 |
Price to Tangible BV |
4.02 | 4.96 | 13.80 | 6.60 | 6.93 | 13.44 | 9.04 | 4.31 | 11.31 | 6.52 |
EV/Sales |
3.43 | 2.39 | 6.36 | 4.30 | 6.66 | 17.61 | 16.52 | 7.03 | 27.14 | 161.81 |
EV/EBITDA |
33.08 | 9.63 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
33.48 | 14.49 | 276.42 | (19.49) | (25.67) | (57.13) | (37.05) | (9.40) | (15.57) | (13.46) |
EV/FCF |
(39.55) | 19.51 | (197.73) | (19.30) | (25.44) | (54.11) | (36.78) | (9.28) | (15.51) | (13.36) |
Quick Ratio |
3.49 | 2.18 | 2.13 | 3.82 | 6.10 | 6.44 | 9.83 | 8.42 | 7.34 | 12.59 |
Current Ratio |
3.83 | 2.38 | 2.42 | 4.04 | 6.43 | 6.77 | 10.16 | 8.83 | 7.62 | 12.87 |
Net Debt/EBITDA |
(7.37) | (3.18) | 5.82 | 1.86 | 3.16 | 2.24 | 2.82 | 1.93 | 1.18 | 1.95 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.03% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.78 | 0.99 | 1.09 | 0.80 | 0.65 | 0.56 | 0.51 | 0.48 | 0.26 | 0.04 |
Operating CF/Net income |
0.28 | 0.70 | (0.27) | 0.53 | 0.75 | 0.48 | 0.64 | 0.68 | 0.75 | 0.77 |
Capex/Depreciation |
(0.74) | (0.08) | 20.22 | 0.00 | (0.20) | (1.72) | 1.33 | (0.87) | (0.34) | (4.96) |
| 39.89% | 38.89% | (14.73%) | (45.89%) | (28.75%) | (42.47%) | (39.93%) | (60.22%) | (67.80%) | (75.58%) | |
| 28.42% | 23.39% | (9.17%) | (33.54%) | (22.64%) | (35.97%) | (35.55%) | (53.03%) | (61.21%) | (69.32%) | |
ROIC |
16.07% | 0.00% | 0.00% | 0.00% | (527.66%) | 0.00% | (9,032.28%) | (2,782.02%) | 0.00% | 0.00% |
Return on Tangible Assets |
49.34% | 41.35% | (16.72%) | (55.62%) | (31.69%) | (45.36%) | (34.16%) | (52.19%) | (88.47%) | (53.38%) |
Average Days of Receivables |
50.49 | 39.90 | 51.43 | 44.51 | 49.26 | 41.55 | 40.77 | 45.32 | 53.86 | 150.37 |
Research and Development Expense of Revenue |
30.69% | 31.66% | 48.40% | 69.91% | 49.45% | 72.24% | 70.89% | 83.63% | 119.45% | 572.87% |
Selling, General and Administrative Expense of Revenue |
51.23% | 50.99% | 55.97% | 71.36% | 81.80% | 87.98% | 96.04% | 118.74% | 204.21% | 1,075.85% |
Intangible Assets out of Total Assets |
0.07 | 0.10 | 0.09 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 |
Share Based Compensation of Revenue |
4.87% | 7.00% | 9.14% | 13.19% | 13.14% | 19.11% | 24.26% | 36.44% | 60.47% | 318.88% |
Graham Net Nets |
0.16 | 0.16 | 0.06 | 0.12 | 0.12 | 0.07 | 0.11 | 0.23 | 0.09 | 0.15 |
Graham Number |
19.51 | 11.63 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
8.69% | 7.41% | (1.24%) | (8.21%) | (4.50%) | (3.37%) | (3.74%) | (12.06%) | (7.72%) | (8.13%) |
Free Cash Flow Yield |
(2.07%) | 3.85% | (0.46%) | (4.36%) | (3.38%) | (1.71%) | (2.42%) | (8.28%) | (5.86%) | (6.30%) |
Revenue per Share |
6.36 | 5.78 | 4.43 | 3.20 | 3.02 | 2.81 | 2.30 | 1.77 | 1.02 | 0.15 |
Operating CF per Share |
0.65 | 0.95 | 0.10 | (0.71) | (0.78) | (0.87) | (1.03) | (1.32) | (1.78) | (1.80) |
Capex per Share |
(0.03) | 0.00 | (0.24) | 0.00 | (0.01) | (0.05) | (0.01) | (0.02) | (0.01) | (0.08) |
Free Cash Flow per Share |
0.62 | 0.95 | (0.14) | (0.71) | (0.79) | (0.91) | (1.03) | (1.34) | (1.78) | (1.88) |
Cash per Share |
4.87 | 4.56 | 2.68 | 2.58 | 3.24 | 4.02 | 4.74 | 3.74 | 2.78 | 4.57 |
Shareholders Equity per Share |
7.29 | 4.42 | 2.64 | 2.48 | 3.37 | 3.99 | 4.75 | 3.78 | 2.73 | 4.47 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
7.29 | 4.42 | 2.64 | 2.48 | 3.37 | 3.99 | 4.75 | 3.78 | 2.73 | 4.47 |
Free Cash Flow |
105.15 | 157.20 | (23.35) | (114.03) | (126.78) | (143.75) | (152.26) | (169.57) | (218.57) | (217.91) |
Working Capital |
785.00 | 543.45 | 361.87 | 382.31 | 521.76 | 611.65 | 685.42 | 466.54 | 324.45 | 505.31 |
Capital Expenditures |
(4.69) | (0.52) | (40.05) | — | (1.12) | (7.59) | (1.13) | (2.10) | (0.81) | (9.51) |
Net Current Asset Value |
725.31 | 483.36 | 298.92 | 320.54 | 458.60 | 562.01 | 676.20 | 464.98 | 324.26 | 505.16 |
EV/EBIT |
35.08 | 9.90 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.06 | 0.00 | 0.00 | 0.02 | 0.00 | 0.01 | 0.01 | 0.55 |
Price to Operating Income |
42.90 | 13.18 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.84 | 1.56 | (0.43) | (0.12) | 0.71 | 0.48 | (0.27) | 0.73 | 0.91 | 0.62 |
Cash ROIC |
5.14% | 10.56% | (2.68%) | (13.95%) | (11.94%) | (11.42%) | (10.90%) | (17.80%) | (32.30%) | (20.80%) |
Accounts Receivable Turnover |
8.47 | 9.25 | 8.78 | 8.06 | 8.37 | 10.02 | 10.33 | 9.68 | 9.77 | 3.95 |
Accounts Payable Turnover |
6.57 | 4.85 | 2.75 | 1.04 | 2.49 | 1.30 | 2.18 | 2.07 | 1.43 | 1.10 |
Inventory Turnover |
3.14 | 2.83 | 1.96 | 1.40 | 2.18 | 1.27 | 2.18 | 2.66 | 1.93 | 0.65 |
Average Days of Payables |
44.72 | 72.21 | 153.78 | 457.63 | 131.12 | 303.59 | 232.37 | 93.40 | 353.30 | 464.35 |
Days of Inventory on Hand |
142.19 | 97.89 | 313.99 | 238.26 | 150.28 | 346.09 | 204.03 | 120.03 | 211.03 | 495.57 |
Average Receivables |
126.46 | 103.52 | 82.72 | 64.21 | 57.81 | 44.08 | 32.83 | 23.11 | 12.79 | 4.39 |
Average Payables |
13.55 | 16.87 | 15.14 | 9.81 | 7.68 | 7.86 | 5.19 | 5.98 | 6.35 | 2.79 |
Average Inventory |
28.31 | 28.88 | 21.23 | 7.26 | 8.78 | 8.01 | 5.21 | 4.66 | 4.71 | 4.71 |
Average Assets |
1,375.98 | 968.36 | 668.38 | 643.97 | 741.37 | 782.90 | 661.69 | 462.35 | 472.83 | 391.52 |
Average Common Equity |
980.09 | 582.27 | 416.08 | 470.65 | 583.95 | 663.07 | 589.11 | 407.18 | 426.85 | 359.09 |
Columns are period end dates